515866
Last Update Posted: 2013-12-20
Recruiting has ended
All Genders accepted | 18 Years + |
68 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Eligibility
Relevant conditions:
Pancreatic Neoplasms
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov